-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on ArriVent BioPharma, Lowers Price Target to $28

Benzinga·11/16/2026 14:04:12
Listen to the news
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $30 to $28.